Citations

Clear

9 citation(s) found for "Liu, Qiang".

Advances in Functional Vascular Stents for Cardiovascular Therapy with Drug Delivery and Computational Design
Xu, Xiaotian , Hu, Yan , Wang, Yu , Sun, Jiayi, Liu, Qiang , Qin, Kai‐Rong , Wang, Yu , Liu, Qiang , Qin, Kairong , Hu, Yan, Li, Haifang

Mayo Clinic

Pharmaceutics | July 20, 2026 | Volume: 18 | Issue: 7 | Pages: 880

10.3390/pharmaceutics18070880 | PMID 42514957 Get It

Vascular stents are crucial devices in the treatment of cardiovascular diseases, and their structural design and function critically affect therapeutic efficacy and patient prognosis. Conventional stents can effectively restore vascular patency by providing mechanical support to blood vessels. However, they still face significant challenges including restenosis, thrombosis, and limited adaptability to complex patient-specific lesion characteristics. To address these limitations, drug delivery offers an important strategy to modulate the pathological microenvironment, enhance long-term vascular healing, and reduce systemic side effects. Meanwhile, advances in computational simulations have provided powerful tools for optimizing stent design through structural mechanics, hemodynamics, and drug release modeling. Computational approaches enable the rational design of stent architectures with improved mechanical stability, vascular compatibility, and therapeutic regulation. Consequently, the development of vascular stents is evolving toward the synergistic integration of drug delivery, structural optimization, and intelligent design. This review summarizes the latest advances in functional vascular stents, clinical applications and computational design. This work aims to provide valuable insights for the engineering of efficient, precise, and intelligent vascular stents for cardiovascular therapies.
Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer
Ying, Yang , Liu, Qiang , Li, Xinyan , Zhang, Hua , Xu, Xin , Nowsheen, Somaira , Li, Ye‐Xiong , Lou, Zhenkun , Zhong, Qiuzi , Deng, Min , Yang, Ying , Nowsheen, Somaira , Li, Ye-Xiong , Lou, Zhenkun , Zhong, Qiuzi , Deng, Min , Liu, Qiang , Zhang, Hua , Ma, Qi , Aziz, Khaled

Mayo Clinic

Science Advances | October 10, 2025 | Volume: 11 | Issue: 41 | Pages: No page available

10.1126/sciadv.adw7989 | PMID 41071892 Get It

Metastatic castration-resistant prostate cancer (mCRPC) progresses aggressively and resists existing therapies. Although poly(ADP-ribose) polymerase inhibitors (PARPis) benefit a subset of patients with mCRPC and BRCA1/2 deficiencies, therapeutic options remain limited for those without such mutations. Here, we uncover a critical role for the ATM-TRMT10A-BRCA1 signaling axis in regulating homologous recombination (HR) repair and PARPi sensitivity. We demonstrate that ATM phosphorylates TRMT10A at serine-28 after DNA damage, promoting BRCA1 recruitment and efficient HR repair. TRMT10A deletion disrupts HR repair, sensitizing cells to PARPis. Moreover, TRMT10A is up-regulated in mCRPC through stabilization by USP10. Targeting USP10 with spautin-1 induces TRMT10A degradation and enhances tumor sensitivity to PARPis in cell-derived xenografts and patient-derived xenograft models. These findings identify TRMT10A as a therapeutic vulnerability in mCRPC and demonstrate that combined inhibition of PARP and USP10 offers a promising synthetic lethal strategy for a broader group of patients lacking classical BRCA mutations.
Intracardiac thrombosis and its management during liver transplantation: international, multicenter, case-control study
Prete, Luca Del , Cazzaniga, Beatrice , Aniskevich, Stephen , Agopian, Vatche G. , Smith, Natalie , Cacioppo, Brian J, Nuti, Anna Maria, Wang, Ryan , Gamboa, Bs Sophia, Groose, Molly K. , Sheth, Mansi, Cywiński, Jacek B. , Wray, Christopher , Hashimoto, Koji , Liu, Qiang , Quintini, Cristiano , Del Prete, Luca , Agopian, Vatche G , Smith, Natalie K , Tu, Chao , Groose, Molly K , Cywinski, Jacek B , Nguyen-Buckley, Christine , Florman, Sander S , Liu, Qiang , Ekser, Burcin , Aniskevich, Stephen , Cacioppo, Brian J., Watson, Christopher, Pai, Sher‐Lu , Nguyen, Christine , Florman, Sander , Croome, Kristopher P. , Ekser, Burcin

Mayo Clinic

International Journal of Surgery | August 22, 2025 | Volume: 111 | Issue: 12 | Pages: 8793-8805

10.1097/js9.0000000000002896 | PMID 40844270 Get It

Background: Intracardiac thrombosis (ICT) during liver transplantation (LT) is a rare but life-threatening complication with limited data regarding its risk factors, management, and outcomes. This study aimed to identify factors associated with ICT development, define predictors of intraoperative outcomes, and propose a novel classification and management algorithm for ICT. Methods: A multicenter, international retrospective case-control study was conducted on liver transplant recipients from seven centers between January 2005 and December 2023. ICT cases were identified through transesophageal echocardiography (TEE) or autopsy and matched 1:1 with controls. Results: Among 11 077 liver transplant recipients screened, 133 patients (1.2%) developed ICT. ICT occurred predominantly after reperfusion (58%). Compared to controls, ICT cases exhibited higher preoperative international normalized ratio ( P = 0.001) and fibrinogen levels ( P = 0.014). Post-reperfusion syndrome ( P < 0.001), disseminated intravascular coagulation ( P < 0.001), and primary graft failure ( P = 0.002) were also more common in the ICT group. Continuous veno-venous hemofiltration during surgery (odds ratio [OR] 8.20, 95% confidence interval [CI]: 2.09–38.1; P = 0.004) was associated with ICT development. ICT was associated with markedly higher rates of cardiac arrest ( P < 0.001) and intraoperative mortality ( P < 0.001), with thrombus location in the left heart chambers representing a significant predictor of mortality (OR 20.7, 95% CI: 6.25–81.3; P < 0.001). ICT grades 2 and 3 were associated with a markedly increased risk of intraoperative cardiac arrest ( P < 0.05). Importantly, delayed use of TEE was strongly associated with intraoperative death (OR 6.27, 95% CI: 1.45–27.1; P = 0.014). The 90-day mortality was 43% in ICT cases compared to 4.5% in controls, while 1-year mortality was 46% versus 10.5%, respectively. Conclusions: ICT during LT is a rare but severe complication associated with intraoperative mortality and poor short-term survival. Coagulation profile and intraoperative management play critical roles in ICT development. The early use of TEE enables timely diagnosis and intervention, improving patient outcomes. We propose a novel ICT classification offering a systematic framework for risk stratification and management to mitigate progression and mortality.
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury
Cheng, Jinping , Jiang, Jingru, He, Baixuan, Lin, Wei‐Jye , Li, Yi , Li, Honghong , Huang, Xiaolong , Xie, Jiatian, Zhang, Zhan , Yang, Yuhua , Xu, Yongteng , Hu, Xia , Wu, Minyi, Zhuo, Xiaohuang , Pei, Yu , Rong, Xiaoming , Ye, Xiaojing , Saw, Phei Er , Wu, Long‐Jun , Mai, Hai‐Qiang , Tang, Yamei , Li, Honghong , Zhang, Zhan , Xu, Yongteng , Shi, Zhongshan , Ye, Xiaojing , Saw, Phei Er , Wu, Long-Jun , Simone, Charles B , Chua, Melvin L K , Tang, Yamei , Duan, Jingjing, Cai, Jinhua , Hu, Xia, Liu, Qiang , Yu, Pei, Simone, Charles B. , Chua, Melvin L.K. , Mai, Hai‐Qiang

Mayo Clinic

Science Translational Medicine | February 22, 2023 | Volume: 15 | Issue: 684 | Pages: No page available

10.1126/scitranslmed.abm6543 | PMID 36812346 Get It

Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon’s minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery–magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues–Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
Denaturation Fingerprinting: Two Related Mutation Detection Methods Especially Advantageous for High G+C Regions
Liu, Qiang, Weinshenker, Brian G. , Wingerchuk, Dean M. , Sommer, Steve S., Weinshenker, Brian G

Mayo Clinic

BioTechniques | August 15, 2018 | Volume: 24 | Issue: 1 | Pages: 140-147

10.2144/98241rr01 | PMID 9454966 Get It

In a Blinded Analysis, Restriction Endonuclease Fingerprinting Detects All the Mutations in a 1.9-kb Segment
Feng, Jinong, Sommer, Steve S., Liu, Qiang

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 23 | Issue: 5 | Pages: 836-839

10.2144/97235bm15 | PMID 9383547 Get It

Inhibition of PCR Amplification by a Point Mutation Downstream of a Primer
Thorland, Erik C., Sommer, Steve S., Liu, Qiang

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 22 | Issue: 2 | Pages: 292-300

10.2144/97222st01 | PMID 9043701 Get It

Bi-directional Dideoxy Fingerprinting (Bi-ddF): Rapid and Efficient Screening for Mutations in the Big Blue TM Transgenic Mouse Mutation Detection System
Sommer, Steve S., Haavik, Jan , Nishino, Hiroshi, Liu, Qiang

Mayo Clinic

BioTechniques | August 2, 2018 | Volume: 20 | Issue: 6 | Pages: 988-994

10.2144/96206bm11 | PMID 8780870 Get It

The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB
Liu, Jieqiong , Mao, Kai, Jiang, Wen , Kim, Betty Y.S. , Liu, Qiang , Jacobs, Lisa K. , Jiang, Shuai , Chen, Kai , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

Oncotarget | December 31, 2015 | Volume: 7 | Issue: 17 | Pages: 24848-24859

10.18632/oncotarget.6664 | PMID 26709538 Get It